Ribatti D
Front Pharmacol. 2024; 15:1384721.
PMID: 38576482
PMC: 10991687.
DOI: 10.3389/fphar.2024.1384721.
Kato K, Noda T, Kobayashi S, Sasaki K, Iwagami Y, Yamada D
Cancer Sci. 2024; 115(5):1520-1535.
PMID: 38475666
PMC: 11093189.
DOI: 10.1111/cas.16144.
Cecchi D, Jackson N, Beckham W, Chithrani D
Pharmaceutics. 2024; 16(2).
PMID: 38399237
PMC: 10891984.
DOI: 10.3390/pharmaceutics16020175.
Thomas J, Gireesh Moly A, Xavier H, Suboj P, Ladha A, Gupta G
Front Oncol. 2023; 13:1063051.
PMID: 37056346
PMC: 10088512.
DOI: 10.3389/fonc.2023.1063051.
Houri A, Mukudai Y, Abe Y, Watanabe M, Nara M, Miyamoto S
Oncol Rep. 2023; 49(5).
PMID: 36896786
PMC: 10035061.
DOI: 10.3892/or.2023.8520.
Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.
Maishi N, Sakurai Y, Hatakeyama H, Umeyama Y, Nakamura T, Endo R
Cancer Sci. 2022; 113(5):1855-1867.
PMID: 35266253
PMC: 9128192.
DOI: 10.1111/cas.15323.
Role of Suprabasin in the Dedifferentiation of Follicular Epithelial Cell-Derived Thyroid Cancer and Identification of Related Immune Markers.
Tan H, Wang L, Liu Z
Front Genet. 2022; 13:810681.
PMID: 35222534
PMC: 8865917.
DOI: 10.3389/fgene.2022.810681.
A New Antitumor Direction: Tumor-Specific Endothelial Cells.
Liang J, Wang S, Zhang G, He B, Bie Q, Zhang B
Front Oncol. 2022; 11:756334.
PMID: 34988011
PMC: 8721012.
DOI: 10.3389/fonc.2021.756334.
Suprabasin: Role in human cancers and other diseases.
Tan H, Wang L, Liu Z
Mol Biol Rep. 2021; 49(2):1453-1461.
PMID: 34775572
DOI: 10.1007/s11033-021-06897-7.
Suprabasin-A Review.
Pribyl M, Hodny Z, Kubikova I
Genes (Basel). 2021; 12(1).
PMID: 33477529
PMC: 7831088.
DOI: 10.3390/genes12010108.
Suprabasin-derived bioactive peptides identified by plasma peptidomics.
Taguchi T, Kodera Y, Oba K, Saito T, Nakagawa Y, Kawashima Y
Sci Rep. 2021; 11(1):1047.
PMID: 33441610
PMC: 7806982.
DOI: 10.1038/s41598-020-79353-4.
An optimal prognostic model based on gene expression for clear cell renal cell carcinoma.
Xu D, Dang W, Wang S, Hu B, Yin L, Guan B
Oncol Lett. 2020; 20(3):2420-2434.
PMID: 32782559
PMC: 7400162.
DOI: 10.3892/ol.2020.11780.
Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes.
Pribyl M, Hubackova S, Moudra A, Vancurova M, Polackova H, Stopka T
Mol Oncol. 2020; 14(10):2403-2419.
PMID: 32696549
PMC: 7530796.
DOI: 10.1002/1878-0261.12768.
Targeting Tumor Endothelial Cells with Nanoparticles.
Sakurai Y, Akita H, Harashima H
Int J Mol Sci. 2019; 20(23).
PMID: 31756900
PMC: 6928777.
DOI: 10.3390/ijms20235819.
Tumor Endothelial Heterogeneity in Cancer Progression.
Maishi N, Annan D, Kikuchi H, Hida Y, Hida K
Cancers (Basel). 2019; 11(10).
PMID: 31600937
PMC: 6826555.
DOI: 10.3390/cancers11101511.
Nanodiamond for Sample Preparation in Proteomics.
Martinez F, Nagl A, Guluzade S, Schirhagl R
Anal Chem. 2019; 91(15):9800-9805.
PMID: 31290325
PMC: 6686154.
DOI: 10.1021/acs.analchem.9b01459.
Interferon-regulated suprabasin is essential for stress-induced stem-like cell conversion and therapy resistance of human malignancies.
Hubackova S, Pribyl M, Kyjacova L, Moudra A, Dzijak R, Salovska B
Mol Oncol. 2019; 13(7):1467-1489.
PMID: 30919591
PMC: 6599850.
DOI: 10.1002/1878-0261.12480.
Genetic analyses of differences between solid and nonsolid predominant lung adenocarcinomas.
Luo J, Ma K, Shi Y, Chen Z, Zhao M, Huang Y
Thorac Cancer. 2018; 9(12):1656-1663.
PMID: 30276966
PMC: 6275839.
DOI: 10.1111/1759-7714.12876.
Network-Based Differential Analysis to Identify Molecular Features of Tumorigenesis for Esophageal Squamous Carcinoma.
Jiang S, Zhang Q, Su Y, Pan L
Molecules. 2018; 23(1).
PMID: 29301256
PMC: 6017464.
DOI: 10.3390/molecules23010088.
ROS enhance angiogenic properties via regulation of NRF2 in tumor endothelial cells.
Hojo T, Maishi N, Towfik A, Akiyama K, Ohga N, Shindoh M
Oncotarget. 2017; 8(28):45484-45495.
PMID: 28525375
PMC: 5542202.
DOI: 10.18632/oncotarget.17567.